Map | A Partnership for Children's Health Search:  Advanced Search
Home General Information Country Support Board Task Forces Resources Media Center
About the Board Last Board Meeting Members Board Reports EC reports Private Access
Printer-friendly format

Quick Reference:

What is GAVI?

GAVI Fact Sheets


Board Documents


Press Releases

Immunization Information

Immunization Forum
Latest Issue

GAVI Update

Fourth GAVI Board Meeting, Noordwijk, The Netherlands, 19 November 2000

Improved immunization systems, products and technologies: GAVI project development agendas

Dr Mark Kane, the Gates Children’s Vaccine Program at PATH, presented a proposal (Word – 40k) from the Working Group to use the current GAVI structure to develop a team approach to addressing the GAVI research priorities.

The Board:

4.1 Approved the basic principles outlined in the paper, confirming that current efforts to help countries introduce new and under-used vaccines and increase basic immunization coverage should remain GAVI’s top priorities, and that human resources should not be shifted away to satisfy new research agendas.

4.2 Endorsed the priority project areas as identified:

  • three vaccine-related projects:
  • to assure the availability, affordability and use of pneumococcal conjugate vaccines for the developing world within seven years. Dr Borst pointed out the possible need to develop simpler and less expensive vaccines than the candidate vaccines currently under development;
  • to assure the development, availability and use of a safe, effective and affordable rotavirus vaccine for the developing world within seven years;
  • to assure the development, availability and use of an affordable meningococcal A or A/C conjugate vaccine for the "meningococcal belt" in Africa within five years;
  • up to three non vaccine-related projects, such as research to improve immunization systems and technologies (specific project recommendations to be provided by the R&D Task Force).

4.3 Urged the Working Group to work with the appropriate task forces and consult with those in the public and private sectors already engaged in the three vaccine-related project areas to identify:

  • the gaps that need to be addressed to move products from their current pre-licensed state to being fully developed, manufactured and delivered to children in developing countries;
  • the lead partners that will be responsible for developing project proposals.

4.4 Endorsed the proposed steps the task forces need to take immediately in order to contribute their expertise to vaccine-related project development agendas.

4.5 Requested the Working Group and the task force(s) concerned to jointly report back to the Board regarding the development of project organization and financing, before the next Board meeting (June 2001).

4.6 Accepted the responsibility of reviewing the refined project agendas approving fully developed proposals for implementation.

4.7 Recommended that the Vaccine Fund use sub-account 3 to address the specific bottlenecks constraining the rapid development and availability of priority products or technologies. If approved by the Fund Board, the Working Group would work closely with the Executive Committee of the Fund to develop the criteria for drawing on sub-account 3.


[ star_int ]   Contact us | Guestbook | Copyrights | Illustrated site